Health related quality of life utility weights for economic evaluation through different stages of chronic kidney diseas
- PDF / 1,332,182 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 7 Downloads / 144 Views
(2020) 18:310
REVIEW
Open Access
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review Jacie T. Cooper1, Andrew Lloyd2 , Juan Jose Garcia Sanchez3* , Elisabeth Sörstadius4, Andrew Briggs1,5 and Phil McFarlane6
Abstract Background: A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses. We applied these recommendations to conduct a systematic review (SR) to identify HSU weights for different stages of chronic kidney disease (CKD), renal replacement therapy (RRT) and complications. Methods: MEDLINE® and Embase were searched for interventional and non-interventional studies reporting HSU weights for patients with CKD stages 1–5 or RRT. As per ISPOR Task Force Guidance, study quality criteria, applicability for Health Technology Assessment (HTA) and generalisability to a broad CKD population were used to grade studies as either 1 (recommended), 2 (to be considered if there are no data from grade 1 studies) or 3 (not recommended). Results: A total of 17 grade 1 studies were included in this SR with 51 to 1767 participants, conducted in the UK, USA, Canada, China, Spain, and multiple-countries. Health related quality of life (HRQL) instruments used in the studies included were EQ-5D-3L (10 studies), SF-6D (4 studies), HUI2/HUI3 (1 study), and combinations (2 studies). Although absolute values for HSU weights varied among instruments, HSU weights decreased with CKD severity in a consistent manner across all instruments. Conclusions: This SR identified HSU weights for a range of CKD states and showed that HRQL decreases with CKD progression. Data were available to inform cost-effectiveness analysis in CKD in a number of geographies using instruments acceptable by HTA agencies. Keywords: EQ-5D, SF-6D, HUI, Cost-utility, Cost-effectiveness, Dialysis, Transplant
* Correspondence: [email protected] 3 Health Economics and Payer Evidence Lead, Global Market Access & Pricing, AstraZeneca, Academy House, 136 Hills Road, Cambridge CB2 8PA, UK Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need t
Data Loading...
